Krka, d. d. stock
KRK.WAWSEHealthcareISIN SI0031102120
76Score 76 out of 100, Strong
Price and trend
59 / 100
Price history
+28% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 2.3% above it.
Since February 2024 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 7.7% below its 52-week high. Largest decline in 20 years: 99% (June 2007 to December 2008).
Chart figures for advanced users
- SMA 50$282.12
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$272.08
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$205.32
- The lowest closing price of the last twelve months.
- Resistance$301.45
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Krka, d. d. belongs to the Drug Manufacturers (Specialty & Generic) industry (Slovenia) and, with a market value of $8.43B, is number 31 of 77 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.26B (up 6.9% year on year) and earnings of $447.04M (up 13%).
- MEQIRI Score 76 out of 100 (Strong): rank 50 of 702 in Healthcare, median 53.
Show more
- The P/E is 18.2 (Drug Manufacturers (Specialty & Generic) median 18.9, own median of recent years 11.1).
- Our model puts fair value at $302.07, with the price 8% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $810.81M, financial debt $20.47M.Stability 93
- Reliable dividendNo dividend cut for 14 years.Capital allocation 87
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 94
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and stability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 74 to 76.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
- calm price action
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $251.73 and expensive above $377.59 (uncertainty low, based on the price swings of the past year).
The two parts of the fair value come to $314.69 (cash-flow model) and $289.45 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly below both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 7.8%. At 8.8% the fair value would be $275.83, at 6.8% it would be $341.44.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (18.9).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 7.2% on the twelve months before. Revenue has grown solidly since 2010, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 58%, operating 22%, net 20%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 28 Jan 2027in 76 days
- Last reported
- 23 Jul 2026EPS reported 19.79
Analyst estimates
Earnings estimates have barely changed since 28 Oct 2026.
- Earnings per share
- 15.65+0.1%
- Revenue
- $2.4B−2.5%
- Earnings per share
- 16.31+0.5%
- Revenue
- $2.53B−2.8%
MEQIRI has stored the estimates since 28 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Krka, d. d.
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 76
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- LupinLUPIN.NS $9.79B76
- Eisai4523.T $9.14B62
- Shanghai Fosun Pharmaceutical (Group)600196.SS $9.13B47
- H. LundbeckHLUN-B.CO $8.64B80
- Glenmark PharmaceuticalsGLENMARK.NS $7.98B74
- AlkermesALKS $7.89B53
- Amneal PharmaceuticalsAMRX $7.56B58
- Huadong Medicine000963.SZ $6.9B60
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = PLN 3.9742, $1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 30 Apr 2019)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.